Impact of time to treatment initiation for patients with oral cavity squamous cell carcinoma: a population-based, retrospective study

Figures & data

Figure 1. Depiction of the patients from the Copenhagen Oral Cavity Squamous Cell Carcinoma (COrCa) database included in this study, and reasons for exclusions of the remaining patients.

Figure 2. Median TTI per year for oral cavity squamous cell carcinoma patients diagnosed and/or treated at the University Hospital of Copenhagen in Denmark in the period 2000–2014, with trendline (blue line) and 95% confidence interval (grey area).

Table 1. Baseline characteristics for patients with oral cavity squamous cell carcinoma diagnosed or treated at the University Hospital of Copenhagen, Denmark in the period 2000–2014.

	Overall
	N (%)
Sex
Male	549 (63.7)
Female	313 (36.3)
Age – years
Median [IQR]	62 [55–70]
Year of diagnosis
Median [IQR]	2010 [2006–2012]
TTI – days
Median [IQR]	31 [22–43]
Smoking
Never-smoker	104 (12.8)
Current smoker	566 (69.7)
Former smoker	142 (17.5)
Tumor sublocation
Floor of mouth	322 (37.4)
Tongue	333 (38.6)
Gingiva	96 (11.1)
Other	111 (12.9)
T-stage
1	289 (36.8)
2	279 (35.5)
3	66 (8.4)
4a/4b/4x	151 (19.2)
Unknown	77
N-stage
0	503 (63.8)
1	125 (15.8)
2a/2b/2c	160 (20.3)
3	1 (0.1)
Unknown	73
UICC-stage
I	230 (29.4)
II	176 (22.5)
III	122 (15.6)
IVa/IVb/IVc/IVx	254 (32.5)
Unknown	80
Treatment
Surgery	441 (51.2)
Surgery with adjuvant radiotherapy	311 (36.1)
Radiotherapy	110 (12.7)
CCI
0	519 (60.2)
1	146 (16.9)
2	114 (13.2)
3 or above	83 (9.6)

Figure 3. Boxplot depicting relation between TTI and treatment modality for oral cavity squamous cell carcinoma patients diagnosed and/or treated at the University Hospital of Copenhagen in Denmark in the period 2000–2014.

Table 2 . Uni- and multivariate cox regression analyses for patients with oral cavity squamous cell carcinoma diagnosed or treated at the University Hospital of Copenhagen, Denmark in the period 2000–2014, stratified for the time periods 2000–2007 and 2008–2014.

	Overall survival		Recurrence free survival
	Univariate HR (95%CI)	Multivariate HR (95%CI)	Univariate HR (95%CI)	Multivariate HR (95%CI)
TTI-days
5 day increase	1.05 (1.02–1.07)	1.01 (0.98–1.04)	1.04 (1.02–1.07)	1.00 (0.97–1.04)
Sex
Female	Ref	Ref	Ref	Ref
Male	1.22 (1.02–1.46)	1.25 (1.02–1.52)	1.13 (0.95–1.34)	1.12 (0.92–1.35)
Age
5 year increase	1.15 (1.11–1.20)	1.20 (1.14–1.25)	1.13 (1.09–1.17)	1.15 (1.10–1.20)
Smoking
Never smoker	Ref	Ref	Ref	Ref
Current smoker	1.72 (1.26–2.34)	1.72 (1.22–2.45)	1.52 (1.14–2.03)	1.50 (1.09–2.07)
Former smoker	1.34 (0.92–1.94)	1.04 (0.70–1.55)	1.48 (1.06–2.08)	1.14 (0.79–1.64)
UICC-stage
1 stage increase	1.48 (1.37–1.60)	1.47 (1.35–1.59)	1.48 (1.38–1.59)	1.45 (1.34–1.57)
Tumor sublocation
Floor of mouth	Ref	Ref	Ref	Ref
Tongue	0.86 (0.70–1.04)	0.96 (0.77–1.20)	0.88 (0.73–1.06)	0.99 (0.80–1.22)
Gingiva	1.35 (1.03–1.78)	0.79 (0.57–1.10)	1.36 (1.04–1.77)	0.80 (0.58–1.10)
Other	1.39 (1.08–1.81)	1.22 (0.92–1.61)	1.56 (1.22–2.01)	1.34 (1.02–1.76)
CCI
0	Ref	Ref	Ref	Ref
1	1.42 (1.13–1.79)	1.35 (1.06–1.74)	1.28 (1.03–1.60)	1.19 (0.94–1.52)
2	1.58 (1.24–2.01)	1.55 (1.18–2.03)	1.55 (1.23–1.96)	1.51 (1.16–1.97)
3 or above	2.01 (1.53–2.63)	1.94 (1.44–2.62)	1.66 (1.28–2.16)	1.56 (1.16–2.09)

Data availability statement

Data are available upon request to the corresponding author, however requires specific permission from the Danish Patient Safety Authority and the Danish Data Protection Agency which can be applied for.